EXAMINE试验:2型糖尿病患者高敏肌钙蛋白I系列测量与心血管结局
EXAMINE试验纳入近期急性冠脉综合征的2型糖尿病患者,检测基线与6个月高敏肌钙蛋白I(hsTnI)。基线与6个月hsTnI升高均与24个月内心血管事件强相关;6个月hsTnI≥99百分位上限者事件风险增高,无论新发或持续升高。阿格列汀与安慰剂在基线hsTnI升高患者中的心血管事件风险无显著差异。
要点
- 基线与6个月hsTnI升高均与24个月心血管事件发生率强相关(P<0.001)。
- 6个月hsTnI≥99百分位上限者主要终点风险增高:新发升高28.1% vs 8.8%,持续升高22.5% vs 8.8%。
- 基线hsTnI升高患者中阿格列汀与安慰剂心血管事件风险无显著差异(22.3% vs 23.0%,HR 0.87,95%CI 0.60-1.25,P=0.44)。
核心结论
- 系列检测hsTnI显示,相当比例无临床识别事件的2型糖尿病患者存在动态或持续升高的hsTnI,且复发事件风险高;hsTnI可能有助于基于风险制定个体化预防策略。
研究设计与样本
- EXAMINE试验为IIIb期临床结局试验,旨在评估非选择性二肽基肽酶4抑制剂阿格列汀的心血管安全性。
- 纳入2型糖尿病、糖化血红蛋白6.5%–11%(使用胰岛素者7%–11%)、随机化前15–90天内有急性冠脉综合征的患者。
- 本分析采用Abbott ARCHITECT法检测基线与6个月hsTnI,限于急性冠脉综合征后≥30天随机化的患者(n=3808)。
- 主要终点为心血管死亡、心肌梗死或卒中;心血管死亡或心力衰竭为预设的裁定次要终点。
主要发现
- 基线hsTnI可检出(≥1.9 ng/L)者占93%,>99百分位参考上限者占16%。
- 基线与6个月hsTnI升高均与24个月心血管事件发生率强相关(各自P<0.001)。
- 基线与6个月hsTnI均不可检出者未来心血管事件风险最低。
- 6个月hsTnI≥99百分位上限者主要终点风险增高:新发升高组28.1% vs <99百分位上限组8.8%(校正HR 2.65,95%CI 1.64-4.28,P<0.001);持续升高组22.5% vs 8.8%(校正HR 1.90,95%CI 1.33-2.70,P<0.001)。
- 基线hsTnI升高患者中,阿格列汀与安慰剂心血管事件风险无显著差异(22.3% vs 23.0%;HR 0.87,95%CI 0.60-1.25,P=0.44)。
关键数值与推荐
- 基线hsTnI可检出(≥1.9 ng/L)者占93%,>99百分位参考上限者占16%。
- 6个月hsTnI≥99百分位上限且新发升高者主要终点28.1% vs <99百分位上限者8.8%(校正HR 2.65,95%CI 1.64-4.28,P<0.001)。
- 6个月hsTnI≥99百分位上限且持续升高者主要终点22.5% vs <99百分位上限者8.8%(校正HR 1.90,95%CI 1.33-2.70,P<0.001)。
- 基线hsTnI升高患者中阿格列汀组vs安慰剂组心血管事件22.3% vs 23.0%(HR 0.87,95%CI 0.60-1.25,P=0.44)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to describe the relationship between changes in high-sensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes. METHODS: The EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) was a phase IIIb clinical outcomes trial designed to evaluate the cardiovascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 inhibitor. Patients with type 2 diabetes mellitus, glycohemoglobin between 6.5% and 11% (or between 7% and 11% if they were on insulin), and a recent acute coronary syndrome (between 15 and 90 days before randomization) were eligible for the trial. hsTnI was measured using the Abbott ARCHITECT assay at baseline and 6 months in patients randomized in the EXAMINE trial. This analysis was restricted to patients randomized ≥30 days after qualifying acute coronary syndrome to mitigate the potential for persistent hsTnI elevation after acute coronary syndrome (n=3808). The primary end point of the trial was cardiovascular death, myocardial infarction, or stroke. Cardiovascular death or heart failure was a prespecified, adjudicated secondary end point. RESULTS: At baseline, hsTnI was detectable (≥1.9 ng/L) in 93% of patients and >99th percentile upper reference limit in 16%. There was a strong relationship between increasing hsTnI, both at baseline and 6 months, and the incidence of cardiovascular events through 24 months (P<0.001 for each). Patients with undetectable hsTnI at baseline and 6 months were at the lowest risk of future cardiovascular events. Stable patients with hsTnI ≥99th percentile upper reference limit at 6 months were at increased risk of cardiovascular death, myocardial infarction, or stroke compared with patients with hsTnI <99 percentile upper reference limit irrespective of whether hsTnI was newly elevated (28.1% versus 8.8%; adjusted hazard ratio, 2.65; 95% confidence interval, 1.64-4.28; P<0.001) or persistently so (22.5% versus 8.8%; adjusted hazard ratio, 1.90; 95% confidence interval, 1.33-2.70; P<0.001). Alogliptin neither increased nor decreased the risk of cardiovascular events compared with placebo in patients with high baseline hsTnI (22.3% versus 23.0%; hazard ratio, 0.87; 95% confidence interval, 0.60-1.25; P=0.44). CONCLUSIONS: Serial assessment of hsTnI revealed a substantial proportion of patients with type 2 diabetes mellitus without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes mellitus based on risk. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00968708.
引用
- Cavender MA, White WB, Jarolim P, et al. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017. PMID: 28246236. doi:10.1161/CIRCULATIONAHA.116.024632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。